Latest From 4SC AG
This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
4SC AG Chief Science Officer says the German cancer drug developer is conducting a Phase II trial of lead candidate ACE inhibitor resminostat in cutaneous T-cell lymphoma and is hoping for conditional EMA approval in 2019.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- 4SC AG
- Senior Management
Jason Loveridge, PhD, CEO
Frank Hermann, MD, Chief Dev. Officer
Roland Baumgartner, PhD, CSO
Susanne Danhauser-Riedl, MD, CMO
- Contact Info
Phone: (49) 89 700763 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.